Background Background Research studies for the
Research studies for the treatment of the putative prodromal treatment of the putative prodromal phase of psychotic disorders have begunto phase of psychotic disorders have begunto appear. appear.
Aims
Aims To obtain preliminary evidence of
To obtain preliminary evidence of the short-term efficacy and safety of the short-term efficacy and safety of aripiprazole treatment in people with the aripiprazole treatment in people with the psychosis prodrome. psychosis prodrome.
Method Method Fifteen participants meeting
Fifteen participants meeting prodrome criteria (mean age17. 
Results

Results In the mixed-effects repeated-
In the mixed-effects repeatedmeasures analysis, improvement from measures analysis, improvement from baseline on the Scale of Prodromal baseline on the Scale of Prodromal Symptoms total score was statistically Symptoms total score was statistically significant by the first week.No significant by the first week.No participant converted to psychosis and participant converted to psychosis and 13 completed treatment.Neuro-13 completed treatment.Neuropsychological measures showed no psychological measures showed no consistent improvement; mean weight consistent improvement; mean weight gain was1.2 kg. Akathisia emerged in 8 gain was1.2 kg. Akathisia emerged in 8 participants, butthe mean Barnes participants, butthe mean Barnes Akathisia Scale score fell to baseline levels Akathisia Scale score fell to baseline levels by the final visit. Adverse events were by the final visit. Adverse events were otherwise minimal. otherwise minimal.
Conclusions Conclusions Aripiprazole shows a
Aripiprazole shows a promising efficacy and safety profile for promising efficacy and safety profile for the psychosis prodrome.Placebothe psychosis prodrome.Placebocontrolled studies are indicated. controlled studies are indicated.
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The prodromal phase of schizophrenic disThe prodromal phase of schizophrenic disorders has been recognised since the 19th orders has been recognised since the 19th century (Bleuler, 1911) and the possibility century (Bleuler, 1911) and the possibility of treatment during the prodromal phase of treatment during the prodromal phase has a history almost as long (Sullivan, has a history almost as long . Although some studies have begun 1927). Although some studies have begun to investigate methods to prevent progresto investigate methods to prevent progression from the putatively identified prosion from the putatively identified prodromal phase to frank psychosis (Falloon, dromal phase to frank psychosis (Falloon, 1992; McGorry 1992; McGorry et al et al, 2002; Morrison , 2002; Morrison et et al al, 2004; McGlashan , 2004; McGlashan et al et al, 2006 McGlashan et al et al, ), fewer , 2006 , fewer have focused on the acute treatment effects have focused on the acute treatment effects on current symptoms (Woods on current symptoms . , 2003) . Aripiprazole is a relatively new antiAripiprazole is a relatively new antipsychotic medication with limited liability psychotic medication with limited liability for weight gain (Marder for weight gain (Marder et al et al, 2003 (Marder et al et al, ), whose , 2003 , whose mechanism of action differs from other mechanism of action differs from other antipsychotics in that it is a partial agonist antipsychotics in that it is a partial agonist rather than a full antagonist at dopamine rather than a full antagonist at dopamine D D 2 2 receptors (Burris receptors (Burris et al et al, 2002) . The , 2002) . The overall goal of the present pilot study was overall goal of the present pilot study was to obtain preliminary information about to obtain preliminary information about the efficacy and safety of aripiprazole in the efficacy and safety of aripiprazole in relieving symptoms that may be prodromal relieving symptoms that may be prodromal for schizophrenia. for schizophrenia.
METHOD METHOD Sample Sample
Adult participants gave written informed Adult participants gave written informed consent and minors gave written informed consent and minors gave written informed assent with consent from a parent or guarassent with consent from a parent or guardian. Participants were included if they dian. Participants were included if they were treatment-seeking out-patients of 13-were treatment-seeking out-patients of 13-40 years of age who met diagnostic criteria 40 years of age who met diagnostic criteria for a possible prodromal syndrome. People for a possible prodromal syndrome. People were excluded for any of the following were excluded for any of the following reasons: (a) past or current DSM-IV criterreasons: (a) past or current DSM-IV criteria (American Psychiatric Association, 1994) ia (American Psychiatric Association, 1994) for any lifetime psychotic disorder; (b) they for any lifetime psychotic disorder; (b) they were judged clinically to have a psychiatric were judged clinically to have a psychiatric disorder (e.g. mania, depression, attentiondisorder (e.g. mania, depression, attentiondeficit hyperactivity disorder) which could deficit hyperactivity disorder) which could account for the symptoms; (c) they preaccount for the symptoms; (c) they presented with symptoms occurring primarily sented with symptoms occurring primarily as sequelae to drug or alcohol use; (d) alcoas sequelae to drug or alcohol use; (d) alcohol or drug misuse or dependence in the hol or drug misuse or dependence in the past 3 months; (e) use of antipsychotic past 3 months; (e) use of antipsychotic medication in the previous 3 months; (f) medication in the previous 3 months; (f) change in dosage of any antidepressant change in dosage of any antidepressant within 6 weeks, stimulant medication withwithin 6 weeks, stimulant medication within 4 weeks, or mood stabiliser within 4 in 4 weeks, or mood stabiliser within 4 weeks. weeks.
The Criteria of Prodromal Syndromes The Criteria of Prodromal Syndromes (COPS; Woods (COPS; ) were used to , 2001) were used to identify those possibly prodromal. The identify those possibly prodromal. The COPS are based on sub-threshold levels COPS are based on sub-threshold levels of positive symptoms and operationally deof positive symptoms and operationally define three prodromal syndromes (Yung fine three prodromal syndromes (Yung et et al al, 1998) : attenuated positive symptom , 1998): attenuated positive symptom syndrome, brief intermittent psychotic syndrome, brief intermittent psychotic syndrome, and genetic risk and recent syndrome, and genetic risk and recent functional decline syndrome. The COPS functional decline syndrome. The COPS and the three syndromes are described in and the three syndromes are described in detail elsewhere (Woods detail elsewhere Miller et al et al, 2003 Miller et al et al, , 2003a . Individuals were assessed to ). Individuals were assessed to determine whether the COPS were met by determine whether the COPS were met by using the Structured Interview for Prodrousing the Structured Interview for Prodromal Syndromes (SIPS; Miller mal Syndromes (SIPS; Miller et al et al, 1999) . , 1999). Reliability of the COPS diagnosis of posReliability of the COPS diagnosis of possible prodrome has been excellent when sible prodrome has been excellent when using the SIPS (Miller using the SIPS (Miller et al et al, 2002 (Miller et al et al, , 2003 (Miller et al et al, , 2002 (Miller et al et al, , 2003a This was an open-label study at one site for 8 weeks, followed by study at one site for 8 weeks, followed by an open-label extension phase with an open-label extension phase with monthly follow-up visits to 52 weeks. monthly follow-up visits to 52 weeks. Findings from the extension phase will be Findings from the extension phase will be reported subsequently. reported subsequently.
Procedure Procedure
During the 1-2 weeks prior to beginning During the 1-2 weeks prior to beginning study medication, participants underwent study medication, participants underwent eligibility and neuropsychological examinaeligibility and neuropsychological examinations. After beginning study medication, tions. After beginning study medication, participants were scheduled for eight participants were scheduled for eight weekly visits. weekly visits.
Dosing followed a fixed-flexible schedDosing followed a fixed-flexible schedule. Initial doses were 5 mg/day aripipraule. Initial doses were 5 mg/day aripiprazole; after 1 week, the dose was scheduled zole; after 1 week, the dose was scheduled for increase to 10 mg/day and after 2 weeks for increase to 10 mg/day and after 2 weeks to 15 mg/day, unless adverse effects dicto 15 mg/day, unless adverse effects dictated a slower titration schedule. After the tated a slower titration schedule. After the third week, the dose could be increased third week, the dose could be increased further to 20 mg/day and if needed to further to 20 mg/day and if needed to 30 mg/day should the person not be re-30 mg/day should the person not be responding. Aripiprazole was prescribed as sponding. Aripiprazole was prescribed as a single daily dose unless there was a reason a single daily dose unless there was a reason to divide the dose. The number of millito divide the dose. The number of milligrams prescribed and the number taken grams prescribed and the number taken were recorded each day; these data were were recorded each day; these data were used to calculate the percentage adherence used to calculate the percentage adherence since the previous visit. Drowsiness was since the previous visit. Drowsiness was managed initially by switching the timing managed initially by switching the timing of the daily dose to bedtime or by dividing of the daily dose to bedtime or by dividing the dose. Insomnia was managed initially the dose. Insomnia was managed initially by switching the timing of the daily dose by switching the timing of the daily dose to early morning. Lorazepam was used to to early morning. Lorazepam was used to treat insomnia or agitation. Lorazepam or treat insomnia or agitation. Lorazepam or the anticholinergic benztropine was perthe anticholinergic benztropine was permitted for extrapyramidal symptoms mitted for extrapyramidal symptoms (EPS). Participants continued doses of anti-(EPS). Participants continued doses of antidepressant, mood stabiliser, or stimulant depressant, mood stabiliser, or stimulant medication prescribed before consent but medication prescribed before consent but were not permitted to begin or increase dowere not permitted to begin or increase dosage of these medications after consent. sage of these medications after consent. Individual and family psychosocial interIndividual and family psychosocial interventions with supportive and psychoeducaventions with supportive and psychoeducational components were available to each tional components were available to each participant. participant.
Assessments Assessments
The primary efficacy measure for the analyThe primary efficacy measure for the analysis of acute treatment was change over time sis of acute treatment was change over time in the total score of the Scale of Prodromal in the total score of the Scale of Prodromal Symptoms (SOPS; Miller Symptoms (SOPS; Miller et al et al, 1999 Miller et al et al, ), a 19-, 1999 , a 19-item scale with items scored 0-6. The interitem scale with items scored 0-6. The interrater reliability has been excellent (Miller rater reliability has been excellent (Miller et et al al, 2003 (Miller et et al al, , 2003a . Factor analysis supports the val-). Factor analysis supports the validity of the SOPS sub-scales (Hawkins idity of the SOPS sub-scales (Hawkins et et al al, 2004 (Hawkins et et al al, , 2004b . Treatment response was defined ). Treatment response was defined as all five SOPS positive symptom items as all five SOPS positive symptom items being rated below the prodromal range being rated below the prodromal range (i.e. (i.e. 4 42). 2). Secondary efficacy assessments inSecondary efficacy assessments included the Calgary Depression Scale for cluded the Calgary Depression Scale for Schizophrenia (CDSS; Addington Schizophrenia (CDSS; Addington et al et al, , 1990) Abnormal involuntary movements and Abnormal involuntary movements and EPS were assessed by observation and ad-EPS were assessed by observation and administration of the Simpson-Angus Scale ministration of the Simpson-Angus Scale (SAS; , the Barnes (SAS; , the Barnes Akathisia Scale (BAS; Barnes, 1989) , and Akathisia Scale (BAS; Barnes, 1989) , and the Abnormal Involuntary Movement Scale the Abnormal Involuntary Movement Scale (AIMS; Branch, 1975) . Safety was also (AIMS; Branch, 1975) . Safety was also assessed by analysing treatment-emergent assessed by analysing treatment-emergent adverse events (Systematic Assessment For adverse events (Systematic Assessment For Treatment-Emergent Events, SAFTEE, speTreatment-Emergent Events, SAFTEE, specific inquiry method; Levine & Schooler, cific inquiry method; Levine & Schooler, 1986) , vital signs and weight. Treatment-1986) , vital signs and weight. Treatmentemergent adverse events were defined as emergent adverse events were defined as those first occurring or worsening after those first occurring or worsening after baseline. All of the above measures were baseline. All of the above measures were assessed at baseline and weekly thereafter. assessed at baseline and weekly thereafter.
Statistical analyses Statistical analyses
For the present report, the time frame was For the present report, the time frame was the first 8 weeks after beginning study the first 8 weeks after beginning study medication, and the principal outcome medication, and the principal outcome measure was the SOPS total score. Analyses measure was the SOPS total score. Analyses were based on the intent-to-treat (ITT) were based on the intent-to-treat (ITT) principle. All participants were included in principle. All participants were included in the analysis. The principal outcome meathe analysis. The principal outcome measure was addressed using a mixed-effects sure was addressed using a mixed-effects likelihood-based repeated measures linear likelihood-based repeated measures linear model (MMRM, as implemented in SAS model (MMRM, as implemented in SAS PROC MIXED) on post-baseline change PROC MIXED) on post-baseline change scores, using baseline scores as a covariate. scores, using baseline scores as a covariate. For other measures we used For other measures we used t t-test end-point -test end-point models at 8 weeks, carrying forward the models at 8 weeks, carrying forward the last observation (LOCF). last observation (LOCF).
RESULTS RESULTS
Participants Participants
A total of 15 participants were enrolled. A total of 15 participants were enrolled. Demographic and treatment characteristics Demographic and treatment characteristics at baseline are shown in Table 1 . All were at baseline are shown in Table 1 . All were diagnosed with the common attenuated diagnosed with the common attenuated positive symptom syndrome putative propositive symptom syndrome putative prodrome subtype according to the COPS drome subtype according to the COPS and none also qualified for either of the and none also qualified for either of the other two less common COPS prodromal other two less common COPS prodromal syndromes. All but two had never received syndromes. All but two had never received antipsychotic medication prior to particiantipsychotic medication prior to participating. One participantt had received antipating. One participantt had received antipsychotic for 5 weeks 5 years earlier, and psychotic for 5 weeks 5 years earlier, and the other for 6 months ending 17 months the other for 6 months ending 17 months before baseline, both for indications other before baseline, both for indications other than psychosis. Scores for severity of illness than psychosis. Scores for severity of illness at baseline are shown in Table 2 . Although at baseline are shown in Table 2 . Although there are a dearth of age-specific normative there are a dearth of age-specific normative data (our sample with test-retest data has a data (our sample with test-retest data has a mean age of 15.5 years, s.d. mean age of 15.5 years, s.d.¼1.3), baseline 1.3), baseline data (Table 3) suggest mild neuropsychodata (Table 3) suggest mild neuropsychological impairment similar to that observed logical impairment similar to that observed in our previous prodromal sample (Hawkins in our previous prodromal sample (Hawkins et al et al, 2004 (Hawkins et al et al, , 2004a . A higher mean AVLT total ). A higher mean AVLT total score was reported for a younger sample score was reported for a younger sample by and substanby and substantially better Trail-Making Part A and Part tially better Trail-Making Part A and Part B performances were reported for a healthy B performances were reported for a healthy sample aged 15-17 years by Fromm-Auch sample aged 15-17 years by Fromm-Auch & Yeudall (1983 ). & Yeudall (1983 .
Thirteen participants completed the 8-Thirteen participants completed the 8-week study (87%). Of the two drop-outs, week study (87%). Of the two drop-outs, one completed 48 days on aripiprazole one completed 48 days on aripiprazole and dropped out because of improvement, and dropped out because of improvement, feeling medication was no longer needed. feeling medication was no longer needed. The other completed only 8 days on mediThe other completed only 8 days on medication and left the study primarily because cation and left the study primarily because of sedation after the first 10 mg dose, after of sedation after the first 10 mg dose, after having concluded that 5 mg was ineffective having concluded that 5 mg was ineffective after the first week. after the first week.
Medication Medication
Prescribed mean (s.d.) aripiprazole doses at Prescribed mean (s.d.) aripiprazole doses at weeks 1, 2, 3, 4, 5, 6, 7 and 8 were 5 (0), 9 weeks 1, 2, 3, 4, 5, 6, 7 and 8 were 5 (0), 9 (2), 11 (5), 11 (7), 11 (6), 13 (6), 14 (8), and (2), 11 (5), 11 (7), 11 (6), 13 (6), 14 (8), and 15 (7) mg/day, respectively. Final pre-15 (7) mg/day, respectively. Final prescribed doses were 5 mg/day ( scribed doses were 5 mg/day (n n¼1 parti-1 participant), 10 mg/day ( cipant), 10 mg/day (n n¼3), 15 mg/day 3), 15 mg/day (s.d. (s.d.¼7) ( 7) (n n¼6), 20 mg/day ( 6), 20 mg/day (n n¼4) and 4) and 30 mg/day ( 30 mg/day (n n¼1). Reported mean (s.d.) per-1). Reported mean (s.d.) percentage adherence with prescribed aripipracentage adherence with prescribed aripiprazole doses was 94 (13), 92 (22), 98 (4), 96 zole doses was 94 (13), 92 (22), 98 (4), 96 (8), 97 (7), 95 (10), 98 (5), and 94 (9) at (8), 97 (7), 95 (10), 98 (5), and 94 (9) at weeks 1, 2, 3, 4, 5, 6, 7 and 8 respectively. weeks 1, 2, 3, 4, 5, 6, 7 and 8 respectively. New concomitant medication used after New concomitant medication used after s 9 7 s 9 7 enrollment included benzodiazepine in enrollment included benzodiazepine in three participants (20%) and anticholinerthree participants (20%) and anticholinergic medication in 5 participants (33%). gic medication in 5 participants (33%).
Efficacy Efficacy
In the mixed-effects model, the effect of In the mixed-effects model, the effect of time for the SOPS total score change from time for the SOPS total score change from baseline was statistically significant ( baseline was statistically significant (F F (7) (7)¼9.2, 9.2, P P5 50.001. The reduction in the 0.001. The reduction in the SOPS total score was statistically signifi-SOPS total score was statistically significant at each time point (Fig. 1) . The LOCF cant at each time point (Fig. 1) . The LOCF analyses revealed that improvement on the analyses revealed that improvement on the SOPS was statistically significant at end-SOPS was statistically significant at endpoint for each of the positive, negative, point for each of the positive, negative, disorganisation and general symptom subdisorganisation and general symptom subscales ( Table 2 ). The LOCF analyses also scales ( Table 2 ). The LOCF analyses also revealed significant symptomatic improverevealed significant symptomatic improvement from baseline on the YMRS, CDSS ment from baseline on the YMRS, CDSS and BAI scales, as well as significant funcand BAI scales, as well as significant functional improvement on the GAF and HCRF tional improvement on the GAF and HCRF scales (Table 2) . scales (Table 2) .
A total of 11 participants met response A total of 11 participants met response criteria (73%) at week 2 ( criteria (73%) at week 2 (n n¼1), 3 ( 1), 3 (n n¼2), 4 2), 4 ( (n n¼1), 6 ( 1), 6 (n n¼4), 7 ( 4), 7 (n n¼1) and 8 ( 1) and 8 (n n¼2). 2). Response was sustained thereafter until Response was sustained thereafter until end-point in all but one participant. No end-point in all but one participant. No participant converted to psychosis. Two participant converted to psychosis. Two non-responders who completed the 8-week non-responders who completed the 8-week course elected not to continue aripiprazole course elected not to continue aripiprazole after 8 weeks; the remaining 11 who after 8 weeks; the remaining 11 who completed 8 weeks elected to continue on completed 8 weeks elected to continue on aripiprazole into the extension phase. aripiprazole into the extension phase. Table 3 shows the results of the neuro- Table 3 shows the results of the neuropsychological testing. Participants improved psychological testing. Participants improved as a group on two tests of attention and as a group on two tests of attention and working memory at the significant or trend working memory at the significant or trend level (2-digit CPT reaction time, 2-back level (2-digit CPT reaction time, 2-back number correct) but worsened on one other number correct) but worsened on one other (2-digit CPT performance). They improved (2-digit CPT performance). They improved as a group on a test of executive functionas a group on a test of executive functioning (WCST perseverative errors) but woring (WCST perseverative errors) but worsened on another (semantic fluency). sened on another (semantic fluency). Scores on the remaining 15 tests of attenScores on the remaining 15 tests of attention, working memory, executive functiontion, working memory, executive functioning, processing speed and verbal memory ing, processing speed and verbal memory did not change significantly. did not change significantly.
Safety Safety
One participant discontinued aripiprazole One participant discontinued aripiprazole because of adverse events (sedation after 8 because of adverse events (sedation after 8 days). As determined by the SAFTEE, there days). As determined by the SAFTEE, there were few adverse events of more than mild were few adverse events of more than mild severity (Table 4) . Complaints of adverse severity (Table 4) . Complaints of adverse events tended to remit over time. Other events tended to remit over time. Other than the participant who took medication than the participant who took medication for only 8 days, at the final evaluation an for only 8 days, at the final evaluation an emergent SAFTEE complaint of moderate emergent SAFTEE complaint of moderate or greater severity was present in only one or greater severity was present in only one participant (nasal congestion). participant (nasal congestion).
During treatment, eight participants During treatment, eight participants experienced emergent akathisia demonexperienced emergent akathisia demonstrated by increases from baseline on the strated by increases from baseline on the BAS. Emergent akathisia was managed by BAS. Emergent akathisia was managed by slowing dose titration (1), prescribing slowing dose titration (1), prescribing anticholinergic medication (2), slowing anticholinergic medication (2), slowing dose titration and prescribing anticholinerdose titration and prescribing anticholinergic medication (2), slowing dose titration gic medication (2), slowing dose titration and prescribing benzodiazepine (2) and preand prescribing benzodiazepine (2) and prescribing anticholinergic medication and scribing anticholinergic medication and then adding benzodiazepine (1). In the conthen adding benzodiazepine (1). In the context of these management efforts, all partitext of these management efforts, all participants experiencing emergent akathisia cipants experiencing emergent akathisia completed treatment, and the emergent completed treatment, and the emergent akathisia remitted by the final evaluation akathisia remitted by the final evaluation in six participants. Mean BAS total scores in six participants. Mean BAS total scores consequently returned to baseline by the consequently returned to baseline by the end-point evaluation (Table 5) . Four partiend-point evaluation (Table 5) . Four participants continued to receive medication cipants continued to receive medication for akathisia at the 8-week evaluation. for akathisia at the 8-week evaluation.
Little change from baseline to end-point Little change from baseline to end-point was observed for blood pressure (Table 5) . was observed for blood pressure (Table 5 ). Pulse increased 6 beats per minute on averPulse increased 6 beats per minute on average. There were no significant differences age. There were no significant differences from baseline to end-point on the SAS or from baseline to end-point on the SAS or AIMS scales (Table 5 ). Patients gained a AIMS scales (Table 5) . Patients gained a mean of 1.2 kg in weight (Table 5) . mean of 1.2 kg in weight (Table 5) .
DISCUSSION DISCUSSION
The principal finding of the present study The principal finding of the present study was that those meeting criteria for a schizowas that those meeting criteria for a schizophrenic prodromal syndrome who were phrenic prodromal syndrome who were treated with aripiprazole improved to a treated with aripiprazole improved to a significant degree over an 8-week period significant degree over an 8-week period on the SOPS and other rating scales. Adon the SOPS and other rating scales. Adverse effects were generally mild and verse effects were generally mild and manageable. Important limitations, howmanageable. Important limitations, however, are the small sample size and the use ever, are the small sample size and the use of an uncontrolled, open-label design. of an uncontrolled, open-label design. s 9 8 s 9 8 
Other studies Other studies
No participants converted to psychosis No participants converted to psychosis during the 8-week trial. We would have during the 8-week trial. We would have expected two or three conversions without expected two or three conversions without treatment, based on the placebo group in treatment, based on the placebo group in our previous study (McGlashan our previous study (McGlashan et al et al, , 2006) . Caution is indicated in comparing 2006). Caution is indicated in comparing our current findings with our historical our current findings with our historical placebo group, however, because it is placebo group, however, because it is possible that people volunteering for an possible that people volunteering for an open-label trial could differ from those open-label trial could differ from those volunteering for a placebo-controlled study volunteering for a placebo-controlled study (Woods (Woods et al et al, 2005) . , 2005). This is the second report to our knowThis is the second report to our knowledge to focus on an acute pharmacological ledge to focus on an acute pharmacological treatment of symptoms that can be treatment of symptoms that can be prodromal for schizophrenia. Our findings prodromal for schizophrenia. Our findings can be compared with those from the acute can be compared with those from the acute phase of our previous placebo-controlled phase of our previous placebo-controlled trial of olanzapine (Woods trial of olanzapine , but again one must allow for the different but again one must allow for the different study designs. Participants with established study designs. Participants with established schizophrenia improved less from baseline schizophrenia improved less from baseline to end-point on active medication when to end-point on active medication when placebo-controlled designs were used placebo-controlled designs were used (Woods (Woods et al et al, 2005) . It is not known , 2005). It is not known whether this same effect of design occurs whether this same effect of design occurs with putatively prodromal subjects. with putatively prodromal subjects. However, improvement in prodromal However, improvement in prodromal symptoms and treatment completion rates symptoms and treatment completion rates in participants assigned to aripiprazole in participants assigned to aripiprazole compared favorably with these indices in compared favorably with these indices in participants randomised to olanzapine in participants randomised to olanzapine in our previous study. Participants were our previous study. Participants were slightly more severely ill at baseline in the slightly more severely ill at baseline in the current sample according to the SOPS total current sample according to the SOPS total score, although GAF scores at baseline and score, although GAF scores at baseline and sample demography were similar. Improvesample demography were similar. Improvement on GAF, as well as on mania and dement on GAF, as well as on mania and depression measures, was also more robust in pression measures, was also more robust in the open-label study of aripiprazole than the open-label study of aripiprazole than we had previously observed in a marked we had previously observed in a marked study of olanzapine. study of olanzapine.
Weight gain with aripiprazole also Weight gain with aripiprazole also compared favourably with our previous compared favourably with our previous experience with olanzapine. Participants experience with olanzapine. Participants treated with olanzapine gained a mean of treated with olanzapine gained a mean of 4.5 kg over 8 weeks in LOCF analyses, 4.5 kg over 8 weeks in LOCF analyses, whereas the aripiprazole mean weight gain whereas the aripiprazole mean weight gain in this study was 1.2 kg (Table 5 ) despite in this study was 1.2 kg (Table 5 ) despite being exposed to drug for a higher proporbeing exposed to drug for a higher proportion of the 8 weeks. This degree of weight tion of the 8 weeks. This degree of weight gain was comparable to that observed in gain was comparable to that observed in previous short-term studies of aripiprazole previous short-term studies of aripiprazole (mean 0.71 kg (mean 0.71 kg v.
v. no change for placebo; no change for placebo; Marder Marder et al et al, 2003) . , 2003) . Akathisia, on the other hand, was more Akathisia, on the other hand, was more problematic with aripiprazole than it had problematic with aripiprazole than it had been with olanzapine, leading to higher been with olanzapine, leading to higher rates of benztropine prescription. However, rates of benztropine prescription. However, benztropine, or in some cases slowing of benztropine, or in some cases slowing of dose titration or benzodiazepine prescripdose titration or benzodiazepine prescription, was effective in managing this adverse tion, was effective in managing this adverse effect, so that by the final evaluation the net effect, so that by the final evaluation the net effect of treatment on akathisia ratings was effect of treatment on akathisia ratings was similar to what we had observed with similar to what we had observed with olanzapine. olanzapine.
Adherence with prescribed doses was Adherence with prescribed doses was relatively high in this short-term analysis relatively high in this short-term analysis as measured by participant report at each as measured by participant report at each visit. Adherence was similar to or higher visit. Adherence was similar to or higher than with olanzapine in our masked study, than with olanzapine in our masked study, although the latter used a somewhat more although the latter used a somewhat more s 9 9 s 9 9 Table 3  Table 3 Baseline and change from baseline in neuropsychological functioning measures ( Baseline and change from baseline in neuropsychological functioning measures (n n¼10) 10) 477 (79) 477 (79) 27 (60) 27 (60) rigorous pill-count method of monitoring rigorous pill-count method of monitoring adherence (Woods adherence . As for most , 2003). As for most studies, surreptitious non-adherence cannot studies, surreptitious non-adherence cannot be excluded. Future studies should continue be excluded. Future studies should continue to assess adherence in this population. to assess adherence in this population.
Our neuropsychological findings show Our neuropsychological findings show little consistent effect of aripiprazole over little consistent effect of aripiprazole over 8 weeks. Among the 20 results reported, a 8 weeks. Among the 20 results reported, a few tests did show improvement, but others few tests did show improvement, but others showed a decline, with most suggesting litshowed a decline, with most suggesting little change. Considering tests that did tle change. Considering tests that did change, within domain of function there change, within domain of function there appeared to be little consistency in direcappeared to be little consistency in direction. Certainly the limited sample size tion. Certainly the limited sample size would have predisposed our study to low would have predisposed our study to low power to detect possible real effects; on power to detect possible real effects; on the other hand, some gains would be exthe other hand, some gains would be expected on the basis of prior test exposure. pected on the basis of prior test exposure. In the only previous study, to our knowIn the only previous study, to our knowledge, on neuropsychological effects of ledge, on neuropsychological effects of aripiprazole (Kern aripiprazole (Kern et al et al, 2006 (Kern et al et al, ), 169 , 2006 , 169 participants with chronic schizophrenic participants with chronic schizophrenic psychosis underwent neuropsychological psychosis underwent neuropsychological examinations before and 8 weeks after ranexaminations before and 8 weeks after random assignment to aripiprazole or olanzadom assignment to aripiprazole or olanzapine. Aripiprazole-treated participants pine. Aripiprazole-treated participants improved significantly over 8 weeks on a improved significantly over 8 weeks on a general cognitive factor on which loaded general cognitive factor on which loaded our letter number sequencing, verbal our letter number sequencing, verbal fluency and trail-making tasks. Our failure fluency and trail-making tasks. Our failure to find consistent improvement on these to find consistent improvement on these measures could relate to our small sample measures could relate to our small sample or to our participants being less impaired or to our participants being less impaired and having less room to improve. Aripipraand having less room to improve. Aripiprazole-treated participants improved signifizole-treated participants improved significantly in the previous study (Kern cantly in the previous study (Kern et al et al, , 2006 ) on a verbal learning factor on which 2006) on a verbal learning factor on which loaded a test similar to our AVLT but withloaded a test similar to our AVLT but without use of alternative forms. Our failure to out use of alternative forms. Our failure to find consistent improvement on verbal find consistent improvement on verbal memory could relate to the small sample, memory could relate to the small sample, studying prodromal studying prodromal v.
v. chronic illness, or, chronic illness, or, our use of a counterbalanced alternate form our use of a counterbalanced alternate form for the repeat verbal learning list, which for the repeat verbal learning list, which may have prevented the confounding of may have prevented the confounding of measurement of new verbal learning by fameasurement of new verbal learning by familiarity with the word list carried over miliarity with the word list carried over from the baseline testing (practice effect; from the baseline testing (practice effect; Hawkins & Wexler, 1999; Hawkins Hawkins & Wexler, 1999; Hawkins et al et al, , 2004 Hawkins et al et al, , 2004c . In the previous study (Kern ). In the previous study (Kern et al et al, , 2006) aripiprazole-treated participants im-2006) aripiprazole-treated participants improved but not significantly on an executive proved but not significantly on an executive functioning factor on which loaded our functioning factor on which loaded our WCST tasks. These findings were similar WCST tasks. These findings were similar to ours with WCST perseverative errors. to ours with WCST perseverative errors.
Dosing Dosing
We paid close attention to the dosing of We paid close attention to the dosing of aripiprazole in the current study. Although aripiprazole in the current study. Although some investigators have emphasised that some investigators have emphasised that patients meeting prodrome criteria can be patients meeting prodrome criteria can be managed with antipsychotic doses which managed with antipsychotic doses which are lower than those used in chronic schizoare lower than those used in chronic schizophrenia (Falloon, 1992; McGorry phrenia (Falloon, 1992; McGorry et al et al, , 2002) , there had been some evidence in 2002), there had been some evidence in our previous study that olanzapine had our previous study that olanzapine had been used at too low a dose, especially in been used at too low a dose, especially in the first month (McGlashan the first month (McGlashan et al et al, 2006 (McGlashan et al et al, ). , 2006 . In the present study we employed a recomIn the present study we employed a recommended fixed dose titration by the end of mended fixed dose titration by the end of the second week to 15 mg/day, the minimal the second week to 15 mg/day, the minimal consistently effective aripiprazole dose for consistently effective aripiprazole dose for patients with chronic schizophrenia patients with chronic schizophrenia , unless the prescriber had , unless the prescriber had a specific reason to deviate from this a specific reason to deviate from this schedule. The 15 mg/day dose was also that schedule. The 15 mg/day dose was also that most commonly employed in a recent pilot most commonly employed in a recent pilot study of aripiprazole in first-episode study of aripiprazole in first-episode schizophrenia (Brown schizophrenia (Brown et al et al, 2003 
Implications Implications
Our current findings are relevant to discusOur current findings are relevant to discussions of the ethics of intervention research sions of the ethics of intervention research in people who appear prodromal. Proin people who appear prodromal. Prodrome research studies thus far have drome research studies thus far have primarily focused on preventing the develprimarily focused on preventing the development of psychosis. Although this is opment of psychosis. Although this is certainly an important goal, ethical issues certainly an important goal, ethical issues are raised because some participants will are raised because some participants will be false-positives who have no personal opbe false-positives who have no personal opportunity to benefit if benefit is defined soportunity to benefit if benefit is defined solely as prevention. The current data suggest lely as prevention. The current data suggest that people carrying a risk of progression to that people carrying a risk of progression to psychosis can receive not only the possipsychosis can receive not only the possibility of a preventive benefit but also a bility of a preventive benefit but also a treatment benefit 'on average' from intertreatment benefit 'on average' from intervention. The prospect of treatment benefit vention. The prospect of treatment benefit on average is generally considered sufficient on average is generally considered sufficient to justify exposure to some treatment risk to justify exposure to some treatment risk in other illnesses. Thus the current data in other illnesses. Thus the current data strengthen the argument that intervention strengthen the argument that intervention studies can be ethical with people who studies can be ethical with people who appear prodromal. appear prodromal. Although our findings suggest that Although our findings suggest that people who meet prodrome criteria benefit people who meet prodrome criteria benefit when prescribed aripiprazole, the present when prescribed aripiprazole, the present results contribute to what is only the beginresults contribute to what is only the beginning of the process of establishing a standning of the process of establishing a standard of care for such people. The sample ard of care for such people. The sample size in our study was small and we had no size in our study was small and we had no control group, placebo or otherwise. Future control group, placebo or otherwise. Future placebo-controlled studies with more partiplacebo-controlled studies with more participants are needed before recommendations cipants are needed before recommendations can responsibly be made regarding routine can responsibly be made regarding routine treatment. The present findings suggest that treatment. The present findings suggest that aripiprazole is a promising candidate for aripiprazole is a promising candidate for such studies. such studies. 
